8 Einträge gefunden

1. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

   1. Reich, Kristian
   2. Papp, Kim A
   3. Blauvelt, Andrew
   4. Langley, Richard G
   5. Armstrong, April
   6. Warren, Richard B
   7. Gordon, Kenneth B

   2021 - Forschungsinformationssystem des UKE
2. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

   1. Gordon, Kenneth B
   2. Foley, Peter
   3. Krueger, James G
   4. Pinter, Andreas
   5. Reich, Kristian
   6. Vender, Ronald
   7. Vanvoorden, Veerle

   2021 - Forschungsinformationssystem des UKE
3. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

   1. Reich, Kristian
   2. Griffiths, Christopher E M
   3. Gordon, Kenneth B
   4. Papp, Kim A
   5. Song, Michael
   6. Randazzo, Bruce
   7. Li, Shu

   2020 - Forschungsinformationssystem des UKE
4. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials

   1. Augustin, Matthias
   2. Lambert, Jo
   3. Zema, Carla
   4. Thompson, Elizabeth H Z
   5. Yang, Min
   6. Wu, Eric Q
   7. Garcia-Horton, Viviana

   2020 - Forschungsinformationssystem des UKE
5. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

   1. Reich, Kristian
   2. Armstrong, April W
   3. Foley, Peter
   4. Song, Michael
   5. Miller, Megan
   6. Shen, Y K
   7. You, Yin

   2020 - Forschungsinformationssystem des UKE
6. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

   1. Reich, Kristian
   2. Song, Michael
   3. Li, Shu
   4. Jiang, Jingzhi
   5. Youn, Sang Woong
   6. Tsai, Tsen-Fang
   7. Choe, Yong Beom

   2019 - Forschungsinformationssystem des UKE
7. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

   1. Gordon, Kenneth B
   2. Armstrong, April W
   3. Foley, Peter
   4. Song, Michael
   5. Shen, Yaung-Kaung
   6. Li, Shu
   7. Muñoz-Elías, Ernesto J

   2019 - Forschungsinformationssystem des UKE
8. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

   1. Gordon, Kenneth B
   2. Strober, Bruce
   3. Lebwohl, Mark
   4. Augustin, Matthias
   5. Blauvelt, Andrew
   6. Poulin, Yves
   7. Papp, Kim A

   2018 - Forschungsinformationssystem des UKE